A delegation of SOM Biotech attended the First European Congress on Hereditary ATTR Amyloidosis that took place in Paris last week (November 2nd – 3rd 2015). During the event, preliminary results of the Phase 2a clinical trial with SOM0226 on ATTR Amyloidosis, which has recently been successfully completed, were presented. This work received a first Prize for Best Presentation. Congratulations to all SOM Biotech team!
More information about the congress can be found at http://www.ec-attr.com